Article
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Human pathology - 1 May 2007
Hornick Jason L, Fletcher Christopher D M
Abstract excerpt
In recent years, immunohistochemical staining for KIT (CD117) has become integral to the diagnosis of gastrointestinal stromal tumors (GISTs), nearly 90% of which harbor activating mutations in the KIT receptor tyrosine kinase gene. Approximately 80% of patients with metastatic GIST show at least some clinical response to the targeted small molecule KIT inhibitor imatinib. The response to imatinib is closely...
Topics
- Antineoplastic Agents
- Benzamides
- Drug Resistance, Neoplasm
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Humans
- Imatinib Mesylate
- Indoles
- Mutation
- Piperazines
- Protein Kinase Inhibitors